Gilead Sciences Inc(GILD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 6:57 PM ET (Korea 10/24 07:57)
Full metrics table
| Index | NDX, S&P 500 | P/E | - | EPS (ttm) | -2.66 | Insider Own | 0.16% | Shs Outstand | 1.24B | Perf Week | -0.1% |
| Market Cap | 193.48B | Forward P/E | 15.59 | EPS next Y | 2516.01% | Insider Trans | -8.28% | Shs Float | 1.24B | Perf Month | 4.24% |
| Enterprise Value | 214.76B | PEG | 1.59 | EPS next Q | 2.18 | Inst Own | 92.64% | Short Float | 1.76% | Perf Quarter | 19.55% |
| Income | -3.24B | P/S | 6.33 | EPS this Y | -105.08% | Inst Trans | 0.12% | Short Ratio | 3.6 | Perf Half Y | 19.66% |
| Sales | 30.54B | P/B | 16.37 | EPS next 5Y | 9.79% | ROA | -6.17% | Short Interest | 21.83M | Perf YTD | 27.13% |
| Book/sh | 9.53 | P/C | 39.63 | EPS past 3/5Y | 23.06% 133.64% | ROE | -20.57% | 52W High | -2.78% ($160.51) | Perf Year | 29.24% |
| Cash/sh | 3.94 | P/FCF | 14.95 | Sales past 3/5Y | 2.83% 3.63% | ROIC | -9.09% | 52W Low | 36.85% ($114.02) | Perf 3Y | 101.19% |
| Dividend Est. | $3.3 (2.11%) | EV/EBITDA | 14.64 | EPS Y/Y TTM | -151.43% | Gross Margin | 79.66% | Volatility(W/M) | 2.32% 2.35% | Perf 5Y | 132.06% |
| Dividend TTM | 3.25 | EV/Sales | 7.03 | Sales Y/Y TTM | 6.05% | Oper. Margin | 39.05% | ATR (14) | 3.83 | Perf 10Y | 110.04% |
| Dividend Ex-Date | 2026/9/15 | Quick Ratio | 1.09 | EPS Q/Q | -640.66% | Profit Margin | -10.61% | RSI (14) | 58.43 | Recom | 1.63 |
| Dividend Gr. 3/5Y | 2.67% 3.04% | Current Ratio | 1.27 | Sales Q/Q | 10.73% | SMA20 | 3.32% ($151.03) | Beta | 0.38 | Target Price | $161.36 |
| Payout | 46.6% | Debt/Eq | 2.22 | Earnings | 2026/10/29 | SMA50 | 4.84% ($148.84) | Rel Volume | 1 | Prev Close | $157.19 |
| Employees | 17000 | LT Debt/Eq | 2.01 | EPS/Sales Surpr. | 6.85% 5.47% | SMA200 | 12.37% ($138.86) | Avg Volume(3M) | 6.06M | Price | $156.04 |
| IPO | 1992/1/22 | Option/Short | Yes/Yes | Trades | 48863 | Volume | 6,070,936 | Change | -0.73% |
💊 Gilead Sciences (GILD) is a U.S.-based global large-cap pharmaceutical company that has established a leading position in the field of antiviral and HIV treatments since its founding in 1987. More recently, the biopharmaceutical company has been pursuing business diversification by expanding its pipeline in oncology and cell therapy.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Next earnings report: October 29
3 days to go.
GILD keeps an operating profit but posts a net loss
Of every $100 in sales, $39.05 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -105.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $633. Peers typically go for $326. Compared with its own 5-year average, it is 11% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +132.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 2.11% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 92.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #8 of 21 in the industry
Based on market cap of $193B.
NVS#5 Novartis AG ADR $277B PER 22.8 
AZN#6 Astrazeneca plc $266B PER 25.6 
AMGN#7 AMGEN Inc $237B PER 27.3 
GILD#8 Gilead Sciences Inc $193B PER - 
PFE#9 Pfizer Inc $171B PER 39.8 
Earnings Analysis · 8/4 Gilead Sciences ($GILD) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Loss Both Beat Expectations; Base Business Guidance Raised, but Shares Edge Lower After Hours Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners FAQ
What kind of company is GILD?
GILD belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of GILD?
The market cap of GILD is approximately $193.5B, ranking 77 within its sector.
Does GILD pay dividends?
GILD has a dividend yield of approximately 2.11%, with an annual dividend of $3.30.
What is the 52-week high and low for GILD?
GILD has recorded a 52-week high of $160.51 and a low of $114.02.
